Results 51 to 60 of about 34,440,044 (184)

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea

Obesity Science & Practice
Background and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian, Yu‐Jie Huang, Cai‐Feng Yan, Shang‐Yong Feng, Dun‐Min She   +4 more
doaj   +1 more source

Euglycemic Ketoacidosis After the Addition of Glucagon-Like Peptide-1 Receptor Agonist: A Case Report

Annals of Internal Medicine: Clinical Cases
Euglycemic diabetic ketoacidosis (euDKA) is an acute, life-threatening metabolic emergency. It has been associated with several factors, including sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Ernest Oji Kanu, Daniel K. Kim, Rejeesh Menon, Carissa Burke, Nathan Vicknair   +4 more
doaj   +1 more source

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update [PDF]

Endocrinology and Metabolism
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic ...
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen   +2 more
doaj   +1 more source

Management of type 2 diabetes mellitus in overweight patients: an updated review

Лечащий Врач
Background. Innovations have been recently proposed in the treatment of type 2 diabetes. Metformin is recommended as a first-line drug now as before; but indications for the use of glucagon-like peptide 1 receptor agonists and sodium-glucose ...
S. V. Jargin
doaj   +1 more source

Tinjauan atas Glucagon-like peptide-1 receptor agonist

Cermin Dunia Kedokteran, 2020
<p>GLP-1 receptor agonist secara struktur mirip hormon alami GLP-1 yang memiliki efek incretin, namun degradasinya dapat dicegah oleh DPP-4. Saat ini terdapat 8 jenis yang terdiri dari exenatide, exenatide ER, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide injeksi, dan semaglitode oral.
openaire   +1 more source

A Scoping Review on Recent Advances in Antidiabetic Medications: From GLP-1 Receptor Agonists to Dual and Triple Agonists

Advances in Clinical Pharmacology and Therapeutics
The management of type 2 diabetes mellitus (T2DM) has evolved substantially with the development of incretin-based therapies targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide (GIP) receptor, and ...
Gulali Aktas
doaj   +1 more source

Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease

Annual Review of Medicine
Glucagon-like peptide 1 receptor (GLP-1R) agonists were originally developed as treatments for diabetes and subsequently evolved into weight management medications. These drugs have recently been shown to demonstrate remarkable efficacy in cardiovascular disease, kidney disease, and heart failure with preserved ejection fraction (HFpEF). In this review,
Tatsuro, Ibe, Barry A, Borlaug
openaire   +2 more sources

Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?

Introduction Parkinson’s disease (PD) is a common neurodegenerative disease. Glucagon-like peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD and are being considered for the treatment of PD.
Doggrell, Sheila A
core   +1 more source

Glucagon-like peptide-1 receptor agonists and muscle mass effects

Pharmacological Research
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of obesity, demonstrating significant efficacy in inducing weight loss and improving metabolic parameters. However, emerging clinical and paraclinical evidence suggests
Alexandr Ceasovschih, Andreea Asaftei, Maria Giovanna Lupo, Stanislav Kotlyarov, Hana Bartušková, Anastasia Balta, Victorita Sorodoc, Laurentiu Sorodoc, Maciej Banach   +8 more
doaj   +1 more source

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

, 2017
Philip A Levin,1 Hiep Nguyen,2 Eric T Wittbrodt,2 Seoyoung C Kim3 1Bay West Endocrinology Associates, Baltimore, MD, 2Health Economics and Outcomes Research, AstraZeneca, Wilmington, DE, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Department
Nguyen H, Kim SC, Levin PA, Wittbrodt ET
core